Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1052W HIGH $1.72
Volume
708.03 K
Value Traded
3.18 K
Short % Float
-
Days to Cover
1.0
-23.1%Week
-28.3%1 Month
-75.37%3 Month
-87.5%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.36 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
49.32 M
Float Shares
14.46 M
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HKPD Catalyst Timeline
Dated clinical, regulatory and corporate events for Cellyan Biotechnology Co., Ltd Class A Ordinary Shares
Past FDA Catalysts and PDUFA Decisions
How HKPD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every HKPD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HKPD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HKPD for Q2 2026. | ||||
HKPD Institutional Ownership Trends
HKPD Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
67.1K
Shares Sold Short
-66.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HKPD ranks across every disease it competes in
Competitive Position is a premium feature
See how HKPD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHKPD News
-HKPD
Oct 21, 2026▼ -20.9%today
Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split
Cellyan Biotechnology announced a 1-for-20 reverse stock split effective October 26, 2026. This move aims to help the company comply with Nasdaq's minimum bid price requirement. The split will consolidate every twenty shares into one, adjusting the par value from $0.001 to $0.02 per share. Fractional shares will be rounded up to the nearest whole share.
Read more →-HKPD
Jul 16, 2026▼ -11.7%on this news
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
Cellyan Biotechnology Co., Ltd has received a 180-day extension from Nasdaq to meet the minimum bid price requirement for its shares. The company must maintain a closing bid price of at least $1.00 for ten consecutive business days by January 11, 2027. While the company is exploring compliance solutions, there are risks regarding its ability to meet Nasdaq's requirements.
Read more →-HKPD
Mar 18, 2026▲ +6.4%on this news
INDEX TO FINANCIAL STATEMENTS Page Consolidated Financial Statements for the Six Months Ended
Cellyan Biotechnology Co., Ltd reported their consolidated financial statements for the six months ended September 30, 2025. The company experienced a significant decline in revenues and net profit when compared to the same period in 2024. Operating expenses are still notable, and there is a marked decrease in overall comprehensive income. The financial position indicates variable performance amidst ongoing economic pressures.
Read more →-HKPD
Jan 19, 2026Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
Cellyan Biotechnology Co., Ltd has received a notification from Nasdaq regarding a deficiency in its bid price, which has been below the required $1.00 for 30 consecutive business days. The company has a compliance period of 180 days to rectify this issue, with the possibility of an additional grace period if necessary. The notification does not currently affect the trading of its shares on Nasdaq.
Read more →-HKPD
Jan 16, 2026Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price
Cellyan Biotechnology Co., Ltd has received a notice from Nasdaq due to its class A ordinary shares' closing bid price falling below the minimum requirement of $1.00 for over 30 consecutive business days. The company has until July 13, 2026, to regain compliance, else it may face additional penalties or possibly implement a reverse share split. While the current notification does not affect trading, the company is exploring options to ensure compliance before the deadline.
Read more →-HKPD
Dec 17, 2025Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) announced the results of its 2025 annual meeting, where all proposals were approved by shareholders. Key measures included the reelection of five directors and the ratification of the appointment of an independent accounting firm. The meeting also approved the increase of authorized share capital and initiated a name change to Cellyan Biotechnology Co., Ltd. This rebranding aligns with the company's focus on expanding its pharmaceutical cross-border e-commerce services.
Read more →-HKPD
Nov 24, 2025▲ +6.1%on this news
Hong Kong Pharma Digital Technology Holdings Limited Room B1, 5 / F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHARE
Hong Kong Pharma Digital Technology Holdings Limited has scheduled its annual general meeting for December 12, 2025. The meeting will cover significant agenda items, including the re-election of five directors, re-appointment of the accounting firm, and proposals related to changes in the share capital structure. Notably, the company is considering a reverse share split and a name change to Cellyan Biotechnology Co., Ltd., subject to shareholder approval. Proxy statements and voting invitations will be mailed to shareholders by November 24, 2025.
Read more →-HKPD
Oct 7, 2025▼ -7.5%on this news
EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the " Agreement" ), is entered into as of [06/10/2025] (the " Effective Date "), by and between Hong Kong Pharma Digital Technology Holdings Limited, a Cayman Islands exemp
Hong Kong Pharma Digital Technology Holdings Limited has signed an employment agreement with Chenyu Liang, appointing him as the Chief Executive Officer. The agreement is effective from June 10, 2025, and is designed to assure the company's leadership stability. It includes provisions such as initial employment for one year, automatic renewal options, and severance benefits under specific termination conditions. The agreement also stipulates the executive's obligations during employment and after termination to protect the company's interests.
Read more →-HKPD
Jan 14, 2025Hong Kong Pharma Digital Technology Holdings Limited Announces Pricing of Initial Public Offering
Hong Kong Pharma Digital Technology Holdings Limited has announced the pricing of its initial public offering (IPO) at $4.00 per share, aiming to raise approximately $4 million. The IPO consists of 1,403,685 ordinary shares, with 1,000,000 shares offered by the company and the remainder by selling shareholders. The company plans to use the net proceeds for upgrading supply chain systems, enhancing warehouse equipment, and expanding its sales and marketing team. Trading is expected to commence on January 15, 2025, under the ticker symbol 'HKPD'.
Read more →About Cellyan Biotechnology Co., Ltd Class A Ordinary Shares
BIOPHARMAWATCH ELITE PLUS
Trade the next HKPD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime